Background There is currently considerable interest in the potential value of selective inhibitors of cyclic nucleotide phosphodiesterase 4 in the treatment of
In 1923, Masson1 described an unusual papillary endothelial proliferation that he named as hemangioendotheliome vegetant intravasculaire. In 1976, Clearkin and